TABLE 2.
Competition assay suggests heterologous HIV-1 strains to be neutralized by fusion peptide-directed plasma responses
| Group | CGP ID | Virus | Plasma dilution or antibody concn | Antibody concn (μg/ml) | Medium %Neut | FP9 |
Scrambled FP9 |
||
|---|---|---|---|---|---|---|---|---|---|
| %Neut | Reduction in Neut (%)a | %Neut | Reduction in Neut (%) | ||||||
| Guinea pig sera | 817-2 | 25710-2.43 | 20 | 77.3 | 48.8 | 37 | 78.3 | −1 | |
| 817-5 | 25710-2.43 | 20 | 53.6 | 35.0 | 35 | 55.4 | −3 | ||
| 820-1 | 25710-2.43 | 20 | 61.7 | 56.7 | 8 | 59.6 | 3 | ||
| 820-2 | 25710-2.43 | 20 | 68.4 | 29.0 | 58 | 66.0 | 3 | ||
| 820-3 | 25710-2.43 | 20 | 65.0 | 60.7 | 6 | 67.7 | −4 | ||
| 820-4 | 25710-2.43 | 20 | 71.2 | 42.2 | 41 | 72.1 | −1 | ||
| CNE19 | 20 | 55.3 | 31.9 | 42 | 55.4 | 0 | |||
| 820-5 | 25710-2.43 | 20 | 88.6 | 7.0 | 92 | 82.0 | 7 | ||
| CNE19 | 20 | 57.6 | 4.8 | 92 | 53.3 | 7 | |||
| 820-6 | 25710-2.43 | 20 | 50.2 | 22.6 | 55 | 49.1 | 2 | ||
| FP antibody | VRC34 | 25710-2.43 | 50 | 45.2 | 8.4 | 81 | 42.2 | 7 | |
| CNE19 | 50 | 73.0 | 53.1 | 27 | 70.4 | 4 | |||
| CD4bs antibody | VRC01 | 25710-2.43 | 2 | 75.0 | 75.5 | −1 | 74.8 | 0 | |
| CNE19 | 0.9 | 75.6 | 74.3 | 2 | 75.1 | 1 | |||
a
Values in reduction in neutralization of greater than the average plus three standard deviations of the scramble FP9 values are shown in bold.